408 related articles for article (PubMed ID: 25781197)
1. Clinical bystander effect exerted by allergen immunotherapy: a hypothesis.
Ciprandi G
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):62-3. PubMed ID: 25781197
[TBL] [Abstract][Full Text] [Related]
2. The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy.
Ciprandi G; Tosca MA; Silvestri M
Expert Rev Clin Immunol; 2014 Mar; 10(3):321-4. PubMed ID: 24450987
[TBL] [Abstract][Full Text] [Related]
3. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy in polysensitized patients: effect on quality of life.
Ciprandi G; Cadario G; Valle C; Ridolo E; Verini M; Di Gioacchino M; Minelli M; Gangemi S; Sillano V; Colangelo C; Pravettoni V; Pellegrino R; Borrelli P; Fiorina A; Carosso A; Gasparini A; Riario-Sforza GG; Incorvaia C; Puccinelli P; Scurati S; Frati F
J Investig Allergol Clin Immunol; 2010; 20(4):274-9. PubMed ID: 20815304
[TBL] [Abstract][Full Text] [Related]
5. How molecular diagnosis may modify immunotherapy prescription in multi-sensitized pollen-allergic children.
Del-Río Camacho G; Montes Arjona AM; Fernández-Cantalejo Padial J; Rodríguez Catalán J
Allergol Immunopathol (Madr); 2018; 46(6):552-556. PubMed ID: 30017214
[TBL] [Abstract][Full Text] [Related]
6. Tolerance and immunological changes of chemically modified allergen vaccine of Parietaria judaica in accelerated schedules.
Asturias JA; Ferrer A; Arilla MC; Andreu C; Madariaga B; Martínez A
Clin Exp Immunol; 2007 Mar; 147(3):491-6. PubMed ID: 17302898
[TBL] [Abstract][Full Text] [Related]
7. Novel strategies for the development of a vaccine for Parietaria allergy.
Bonura A; Colombo P
Int J Immunopathol Pharmacol; 2011; 24(2):297-304. PubMed ID: 21658304
[TBL] [Abstract][Full Text] [Related]
8. [The value and possibilities of immunotherapy in the treatment of allergic rhinitis].
Pfaar O; Hörmann K; Klimek L
MMW Fortschr Med; 2006 Feb; 148(5):28-32. PubMed ID: 16518935
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
Bahceciler NN; Cobanoglu N
Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
[TBL] [Abstract][Full Text] [Related]
10. Ultra-short-course booster allergen immunotherapy.
Pfaar O; Pieper-Fürst U; Mösges R
Immunotherapy; 2018 Jun; 10(7):525-528. PubMed ID: 29562789
[No Abstract] [Full Text] [Related]
11. The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidence.
Passalacqua G
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):20-4. PubMed ID: 24362238
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
[TBL] [Abstract][Full Text] [Related]
13. [Allergic march in children, from rhinitis to asthma: management, indication of immunotherapy].
Scheinmann P; Pham Thi N; Karila C; de Blic J
Arch Pediatr; 2012 Mar; 19(3):330-4. PubMed ID: 22306361
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic approaches in respiratory allergy are different depending on the profile of aeroallergen sensitisation.
Domínguez-Ortega J; Quirce S; Delgado J; Dávila I; Martí-Guadaño E; Valero A
Allergol Immunopathol (Madr); 2014; 42(1):11-8. PubMed ID: 23265263
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
Rossi RE; Monasterolo G
Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
[TBL] [Abstract][Full Text] [Related]
16. Multiallergen-specific immunotherapy in polysensitized patients: where are we?
Bahceciler NN; Galip N; Cobanoglu N
Immunotherapy; 2013 Feb; 5(2):183-90. PubMed ID: 23413909
[TBL] [Abstract][Full Text] [Related]
17. Focusing the mechanism of action to dissect the different treatments of respiratory allergy.
Incorvaia C; Moingeon P; Buttafava S; Frati F
Expert Rev Clin Immunol; 2015; 11(9):1005-13. PubMed ID: 26143936
[TBL] [Abstract][Full Text] [Related]
18. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS).
Migueres M; Fontaine JF; Haddad T; Grosclaude M; Saint-Martin F; Bem David D; Crestani B
Int J Immunopathol Pharmacol; 2011; 24(2):387-400. PubMed ID: 21658313
[TBL] [Abstract][Full Text] [Related]
20. High-dose sublingual immunotherapy in children at 8-year follow-up.
Leonardi S; Spicuzza L; La Rosa M
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):259-60. PubMed ID: 19354077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
